ID   HROC32
AC   CVCL_1D06
SY   HROC32P
DR   cancercelllines; CVCL_1D06
DR   CLS; 300818
DR   Cosmic; 2324290
DR   GEO; GSM1448079
DR   Wikidata; Q54895282
RX   PubMed=25574089;
RX   PubMed=25926053;
RX   PubMed=31601052;
CC   From: Linnebacher, Michael; University of Rostock; Rostock; Germany.
CC   Population: Caucasian.
CC   Doubling time: 32 +- 10.6 hours (PubMed=25574089); 30 hours (CLS=300818).
CC   HLA typing: A*01:01,02:01; B*08:01,03:01; C*07:01,14:02; DPB1*01:01,02:01; DQA1*01:02,05:01; DQB1*02:01,03:01; DRB1*03:01,11:01 (CLS=300818).
CC   Microsatellite instability: Stable (MSS) (PubMed=25926053).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Unspecified (CLS=300818).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (CLS=300818).
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: In situ; Colon, ascending; UBERON=UBERON_0001156.
ST   Source(s): CLS=300818; Direct_author_submission; PubMed=25926053
ST   Amelogenin: X
ST   CSF1PO: 14
ST   D13S317: 11,12 (Direct_author_submission)
ST   D13S317: 12 (CLS=300818; PubMed=25926053)
ST   D16S539: 11,12
ST   D18S51: 12
ST   D21S11: 31
ST   D3S1358: 15,17
ST   D5S818: 11,12 (CLS=300818; Direct_author_submission)
ST   D5S818: 12 (PubMed=25926053)
ST   D7S820: 8,11
ST   D8S1179: 12
ST   FGA: 18,19
ST   Penta D: 12
ST   Penta E: 10
ST   TH01: 8,9
ST   TPOX: 8,11
ST   vWA: 19
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_YD55 ! B-LCL-HROC32
OI   CVCL_1D07 ! HROC32 T3 M1
SX   Female
AG   82Y
CA   Cancer cell line
DT   Created: 08-07-15; Last updated: 10-04-25; Version: 24
//
RX   PubMed=25574089; DOI=10.3748/wjg.v21.i1.164; PMCID=PMC4284332;
RA   Maletzki C., Gock M., Randow M., Klar E., Huhns M., Prall F.,
RA   Linnebacher M.;
RT   "Establishment and characterization of cell lines from chromosomal
RT   instable colorectal cancer.";
RL   World J. Gastroenterol. 21:164-176(2015).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//
RX   PubMed=31601052; DOI=10.3390/cancers11101520; PMCID=PMC6826890;
RA   Mullins C.S., Micheel B., Matschos S., Leuchter M., Burtin F.,
RA   Krohn M., Huhns M., Klar E., Prall F., Linnebacher M.;
RT   "Integrated biobanking and tumor model establishment of human
RT   colorectal carcinoma provides excellent tools for preclinical
RT   research.";
RL   Cancers (Basel) 11:1520.1-1520.18(2019).
//